Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — Q1 FY2024 Earnings Presentation
10 slides from Jagsonpal Pharmaceuticals's earnings presentation, Aug 2, 2023
Slide 1: Jagsonpal Pharmaceuticals Limited Q1FY24 Earnings Presentation
Jagsonpal Pharmaceuticals Limited Q1FY24 Earnings Presentation August 02, 2023
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 3: Q1 FY24 Performance
JAGSONPAL Q1 FY24 Performance
Slide 4: Management Commentary
Management Commentary “The quarter gone by was significant in the journey of Jagsonpal as we reorganized our sales force for sharper doctor alignment as well as creating headroom for new product introductions. We have now transitioned to 3 operating divisions from 2, with two of them focused extensi
Slide 5: Q1FY24 – Steady sales, improving financial performance
Q1FY24 – Steady sales, improving financial performance Business Update (Source: IQVIA) o Strong performance in focus molecules o Dydrogesterone maintains the strong performance, despite hyper competition with 39 competitors o Long-term commitment to molecule continues, gains market share to 3.72% (f
Slide 6: Key Brands Progression
Key Brands Progression All values in ₹ crores IQVIA Sales IQVIA – Market size Molecule Brand MAT June’23 MAT June’22 Gr % MAT June’23 MAT June’22 Gr % Indomethacin Indocap/ SR 40.1 34.6 16% 54 48 12% Hydroxyprogesterone Maintane Inj. 39.9 35.2 13% 156 140 11% Dydrogesterone* Divatrone/ ProRetro 39.1
Slide 7: Financial Performance
JAGSONPAL Financial Performance
Slide 8: Profit and Loss Statement
Profit and Loss Statement All values in ₹ Mn Q1 FY 24 Q4 FY 23 Q1 FY 23 FY 23 Particulars Unaudited Audited Unaudited - Restated Audited Revenue From Operations 602 555 606 2,367 Material Consumption -223 -225 -262 -931 Gross Margin 379 329 344 1,436 % 62.9% 59.4% 56.8% 60.6% Employee Benefit Expens
Slide 9: Key Balance Sheet Items
Key Balance Sheet Items All values in ₹ Mn As at As at Particulars Movements 30 Jun 23 31 Mar 23 Shareholders Funds 1,706 1,589 117 Tangible Assets 182 184 -2 Cash & Equivalents 1,245 1,169 76 Investments 11 11 0 Other Non-Current Assets (Net) 13 13 1 Net Working Capital 273 231 41 9
Slide 10: Thank You
JAGSONPAL Thank You
Jagsonpal Pharmaceuticals — Q1 FY2024 Earnings Presentation on 6ix